Alexion Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Alexion Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alexion Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alexion Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alexion Pharmaceuticals Inc (Alexion), a subsidiary of AstraZeneca Plc, is a pharmaceutical company that discovers, develops and markets therapies for rare and life-threatening diseases. The company's products include sebelipase alfa for treating lysosomal acid lipase deficiency; selumetinib for neurofibromatosis type 1; eculizumab for paroxysmal nocturnal Hemoglobinuria and atypical hemolytic uremic syndrome; asfotase alfa for hypophosphatasia; ravulizumab-cwvz for paroxysmal nocturnal hemoglobinuria and danicopan for paroxysmal nocturnal hemoglobinuria. Alexion also develops therapies for generalized myasthenia gravis. Alexion markets its products under Kanuma, Koselugo, SOLIRIS, STRENSIQ, ULTOMIRIS and Voydeya brands. The company operates in Europe, the Middle East, North America, Latin America, and Asia Pacific. Alexion is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
121 Seaport Boulevard, Boston, Massachusetts, 02210
Website
www.alexion.com
No of Employees
5,000
Industry
Pharmaceuticals and Healthcare
Alexion Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Sebelipase Alfa: Lysosomal Acid Lipase (LAL) Deficiency | Support | Kanuma |
| Selumetinib: Neurofibromatosis Type 1 (NF1) | Health Insurance Navigation | Koselugo |
| Eculizumab: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS) | Disease Information | SOLIRIS |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company signed a partnership with DHL Express to diminish greenhouse gas emissions from the air freight of highly specialized medicines manufactured in Ireland. |
| 2023 | Contracts/Agreements | In September, the company entered into a collaboration with Verge Genomics to identify novel drug targets for rare neurodegenerative and neuromuscular diseases. |
| 2023 | Contracts/Agreements | In July, the company and AstraZeneca Rare Disease entered into an agreement to acquire a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. |
Competitor Comparison
| Key Parameters | Alexion Pharmaceuticals Inc | Novartis AG | Amgen Inc | Regeneron Pharmaceuticals Inc | Baxter International Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Boston | Basel | Thousand Oaks | Tarrytown | Deerfield |
| State/Province | Massachusetts | Basel-Stadt | California | New York | Illinois |
| No. of Employees | 5,000 | 75,267 | 31,500 | 15,410 | 37,500 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marc Dunoyer | Chief Executive Officer | Senior Management | 2021 | - |
| Sean Christie | Chief Financial Officer; Chief Administrative Officer | Senior Management | - | - |
| Sarah Marshall | Head - Human Resource; Vice President | Senior Management | - | - |
| Simone Lauchart | Vice President - Project and Portfolio Management | Senior Management | - | - |
| Todd Spalding | Senior Vice President; Deputy General Counsel | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer